Masimo Corporation has experienced growth in its shares recently, with the Texas Permanent School Fund Corp increasing its position by 33.4% in the first quarter of this year. According to a recent Form 13F filing with the SEC, Texas Permanent School Fund Corp now owns 43,369 shares of Masimo’s stock, after acquiring an additional 10,857 shares during the quarter. This amounts to approximately 0.08% ownership of Masimo and is valued at $8,003,000 as of its most recent filing.
Masimo Corporation is a global leader in developing, manufacturing, and marketing patient monitoring technologies, as well as automation and connectivity solutions. Their innovative products aim to address the limitations of conventional pulse oximetry by offering advanced features such as masimo signal extraction technology (SET) pulse oximetry. This technology enables accurate measurements even in challenging conditions like motion or low perfusion.
One of the key offerings from Masimo is their rainbow SET platform. It includes pulse CO-Oximetry products that allow noninvasive monitoring of various parameters such as carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index. Additionally, they provide acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and O3 regional oximetry.
In other news related to Masimo Corporation’s stock activity, CEO Joe E. Kiani made a significant purchase by acquiring 6,365 shares on May 25th at an average price of $157.16 per share. The total transaction amounted to $1 million (approximately), indicating Mr. Kiani’s confidence in the company’s future prospects. Following this acquisition, he now owns a substantial number of shares totaling 366,055, valued at an impressive $57,529,203.80.
This acquisition was disclosed in a filing with the Securities & Exchange Commission (SEC), and the details of this transaction can be found on the SEC website. It is worth noting that corporate insiders, including CEOs like Joe E. Kiani, have a significant stake in Masimo Corporation, with 9.70% of the stock being owned by internal stakeholders.
Overall, Masimo Corporation’s recent activities in terms of share growth and CEO investment indicate positive prospects for the company’s future. With their focus on developing advanced patient monitoring technologies and connectivity solutions, Masimo continues to be a frontrunner in the medical equipment industry. Investors and shareholders can look forward to these developments as indicators of potential growth and success for the organization moving forward into July 20, 2023.
[bs_slider_forecast ticker=”MASI”]
Masimo Corporation: Revolutionizing Patient Monitoring Technologies
July 20, 2023
Masimo Corporation: A Leader in Patient Monitoring Technologies
Masimo Corporation is a global leader in the development, manufacturing, and marketing of patient monitoring technologies, as well as automation and connectivity solutions. The company’s innovative products have revolutionized the field of medical equipment, particularly in the area of pulse oximetry.
One of Masimo’s key offerings is its patented masimo signal extraction technology (SET) pulse oximetry. This advanced technology addresses the limitations of conventional pulse oximetry by providing accurate readings even during motion and in low perfusion situations. This has greatly improved patient monitoring capabilities, especially in critical care settings.
In addition to SET pulse oximetry, Masimo also offers the rainbow SET platform. This platform enables noninvasive monitoring of various parameters such as carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index. Masimo also provides other monitoring solutions like acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and O3 regional oximetry.
The success of Masimo can be attributed to its commitment to innovation and continuous improvement. The company’s products have garnered praise from both healthcare professionals and investors alike. As evidence of this, several hedge funds and institutional investors have recently increased their holdings in the company. Belpointe Asset Management LLC acquired a new stake in Masimo worth $38,000 during the fourth quarter of last year. Itau Unibanco Holding S.A., on the other hand, raised its stake in Masimo by a staggering 147.5% during the same period.
Equity research analysts have also recognized the potential of Masimo’s stock. StockNews.com recently initiated coverage on Masimo with a “hold” rating. Stifel Nicolaus, however, downgraded the stock from “buy” to “hold” and lowered the price target. Similarly, Wells Fargo & Company and BTIG Research also reduced their price targets for Masimo. Needham & Company LLC remained optimistic about Masimo’s prospects and maintained its “buy” rating on the stock.
Despite mixed opinions from analysts, Masimo continues to thrive in the market. As of today, Masimo Corporation (NASDAQ: MASI) opened at $112.28 per share. The company’s 50-day moving average price is $159.09, while its 200-day moving average stands at $168.97. With a current ratio of 2.16 and a quick ratio of 1.30, Masimo is well-positioned to navigate financial challenges.
Masimo’s stellar performance was also evident in its recent quarterly earnings report. For the quarter ended May 9th, Masimo reported earnings per share (EPS) of $0.87, surpassing the consensus estimate by $0.04. The company achieved a return on equity of 19.32% and a net margin of 5.16%. Additionally, Masimo recorded revenue of $565 million for the quarter, representing an impressive 85.7% increase compared to the same period last year.
Looking ahead, analysts forecast that Masimo will deliver earnings per share of 4.76 for the current year.
In conclusion, Masimo Corporation has established itself as a leader in patient monitoring technologies through its cutting-edge products and solutions such as SET pulse oximetry and rainbow SET platform. The company’s commitment to innovation and continuous improvement has garnered praise from investors as well as healthcare professionals who value accurate and reliable monitoring tools when it comes to patient care.
Note: All information provided is accurate as of July 20th, 2023.
References:
1. Bloomberg.com
2. Masimo Corporation